NN's data-center and medical wins are real. Then came the dilutive $75 million raise.

NN, Inc. gave investors a genuinely good news run and then handed them the bill. On June 30 the company agreed to sell 24,509,804 shares of common stock at $3.06 per share in a private placement, for gross proceeds of about $75 million, with the closing expected on or about July 2 and Craig-Hallum acting as placement agent. The stated use of proceeds is working capital and general corporate purposes, which the company frames as balance-sheet optimization. The market read a large, below-market equity raise for what it is, and the stock traded down on the news.

What makes the timing awkward is that the raise landed on top of two of the best commercial announcements NN has made in a while. On June 29 the company disclosed significant new awards for its NVIDIA data-center liquid-cooling product line. A week later, on July 6, it announced its first purchase orders for robotic-assisted surgery components, after passing a full-facility audit at its Kentwood, Michigan plant, a qualification gate for that market. NN said the new customer relationship expanded its medical new-business pipeline by about $25 million, to roughly $75 million.

The operating story is actually improving

Strip out the raise and NN's underlying numbers are moving the right way. First-quarter net sales were about $118.5 million, up 12.1% year over year, and adjusted EBITDA was $14.1 million, up 33%. On a non-GAAP basis the company reported a small adjusted net profit of about $1.0 million, or $0.02 per share, even though the GAAP result was a net loss of $6.8 million, or $(0.25) per share. Management has said its adjusted gross margin and adjusted EBITDA margin are approaching multi-year targets of 20% and 13%. This is a turnaround that is genuinely turning.

Both new fronts, data-center liquid cooling and robotic-surgery components, are exactly the higher-value, secular-growth end markets NN's turnaround thesis has pointed to. Qualifying for a robotic-surgery platform in particular is not trivial: it takes a multi-year quality investment and a facility audit to get on the approved-supplier list at all.

Why this is a Neutral

The honest problem is the balance sheet. NN is still a levered company that is unprofitable on a GAAP basis, and issuing 24.5 million new shares below market to shore up working capital is dilutive at exactly the wrong price. The growth wins raise the ceiling on the story, but the equity raise lowers the floor, and the market's negative reaction reflected that trade. The bull case that these end-market wins support a re-rating runs straight into a share count that just got materially larger.

• Dilution at a low price. 24.5 million new shares at $3.06 is a meaningful increase in the count, done below market to fund working capital.
• Levered and GAAP-unprofitable. The operating trend is improving, but the company still posted a GAAP net loss and carries a heavy debt load.
• Real end-market wins. NVIDIA data-center cooling and a robotic-surgery qualification are exactly the higher-value markets the turnaround needs.
• Margins approaching targets. Adjusted gross and EBITDA margins are nearing multi-year goals of 20% and 13%.

What to watch

The next test is the second-quarter report and the promised guidance update in August, where the questions are whether the new awards begin to show up in revenue, how the margin trajectory holds, and what the diluted share count and net leverage look like after the placement clears. If the data-center and medical wins convert while margins keep climbing, the raise will look like a bridge to a better balance sheet. If they do not, investors will have paid dilution for wins that took too long to matter. For now, the wins earn respect and the raise earns caution, which nets to Neutral.